Discovery of NAADP-Lysosomal Pathway in 5-HT2A Psychedelic Signaling

New NAADP-Lysosomal Pathway Identified in 5-HT2A Receptor Signaling

Researchers have discovered a previously unknown intracellular signaling pathway linked to the 5-hydroxytryptamine 2A (5-HT2A) receptor, a primary target for both serotonin and classic psychedelic drugs. The study, published on November 3, 2026 (OpenAlex W7225164479), demonstrates that activation of the 5-HT2A receptor triggers not only the well-characterized inositol trisphosphate (IP3) and β-arrestin2 pathways, but also a nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated release of calcium (Ca2+) from lysosomal stores. This mechanism was confirmed using pharmacological inhibition, direct biosensor measurement, and genetic ablation in animal models, suggesting its essential role in both hallucinogenic and neuroplastic effects of psychedelics.

Mechanistic Details: From Receptor to Lysosome

The NAADP-mediated lysosomal Ca2+ signaling pathway represents a significant departure from traditional models of 5-HT2A receptor activity, which have focused on Gq protein coupling and endoplasmic reticulum (ER) calcium mobilization. In this study, application of serotonin and various psychedelic compounds led to measurable increases in cellular NAADP and subsequent Ca2+ release specifically from lysosomal stores, not the ER. Genetic knockout of key components in the NAADP pathway markedly reduced both behavioral (hallucinogenic) and cellular (neuroplastic) responses to psychedelics in mice, indicating that this pathway is not merely ancillary but central to the drugs' effects. This finding may explain observed differences in efficacy and side effect profiles among compounds previously assumed to act via identical downstream mechanisms.

Implications for Drug Development and Clinical Research

The identification of the NAADP-lysosomal pathway as a critical mediator of psychedelic drug action provides a new target for therapeutic innovation. Drug developers may now explore compounds that selectively modulate this pathway, with the potential to separate neuroplastic (potentially therapeutic) effects from hallucinogenic (psychoactive) effects. This mechanistic insight also offers a concrete criterion for evaluating next-generation psychedelics in preclinical and clinical trials: does a candidate compound activate the NAADP-lysosomal pathway, and how does this correlate with clinical endpoints? Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) may require mechanistic data addressing this pathway in future investigational new drug (IND) applications, especially as the field moves toward more targeted interventions.

• Concrete example: A compound that activates 5-HT2A but fails to engage the NAADP pathway may show reduced efficacy in neuroplasticity assays, suggesting a mechanistic biomarker for screening candidates before costly clinical trials.

Risks, Unknowns, and Translational Challenges

While the discovery of the NAADP-lysosomal pathway opens new avenues for research and drug development, several risks and unknowns remain. The translational relevance of these findings from animal models to humans is not yet established, and off-target effects of modulating lysosomal calcium stores are poorly understood. Lysosomal dysfunction is implicated in neurodegenerative diseases, raising questions about the safety of chronic or high-dose modulation of this pathway. Furthermore, the interplay between the NAADP-lysosomal pathway and established signaling routes (IP3, β-arrestin2) is complex, and compensatory mechanisms may confound attempts to selectively target one pathway in vivo. Clinical trials will need to carefully monitor for both efficacy and unexpected adverse events related to lysosomal or calcium homeostasis.

Looking Forward: Next Steps for Research and Policy

Future research will need to validate the role of the NAADP-lysosomal pathway in human subjects, ideally through a combination of molecular imaging, pharmacogenomics, and biomarker-driven clinical trial design. Policy makers and funding agencies may prioritize studies that clarify the safety profile of targeting lysosomal calcium signaling, as well as those that explore potential for non-hallucinogenic neuroplastic agents. The discovery also underscores the importance of mechanistic diversity in psychedelic research, suggesting that not all 5-HT2A agonists are created equal and that rational drug design can now be informed by a more nuanced understanding of intracellular signaling. As the field matures, integration of mechanistic biomarkers into regulatory and clinical frameworks will be essential for safe and effective translation of psychedelic therapies.

By Dr. Alex Greene, PhD (Neuropharmacology). How we research: This article was reviewed by Dr. Alex Greene on 2026-11-05, referencing the original publication and primary regulatory guidance.